119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study

Increasing availability of first-line targeted treatments has made next generation sequencing (NGS) essential for optimal treatment decisions in advanced non-small cell lung cancer (aNSCLC). Factors including biopsy feasibility, sample quality, failure rates and report turn-around times are significant barriers to timely and complete profiling with standard-of-care (SoC) tissue-based genotyping. Blood-based ctDNA NGS technologies may overcome these barriers. NHS England drug commissioning criteria allow treatment based on radiological findings and an informative Tier 1 ctDNA NGS result.

Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Neal Navani, Alexander van Doornewaard, Verena Schneider, Phoebe Marson Smith, Riyaz Shah, Alastair Greystoke, Matthew Krebs, Sophie Scott, Iris Faull, Elisabeth Adams, Sanjay Popat Tags: Other Source Type: research